Thu Sep 19 06:46:56 UTC 2024: ## Cullinan Therapeutics Emerges as the Stronger Stock: MarketBeat Analysis

**Cambridge, MA and San Mateo, CA (September 19, 2024):** In a recent analysis, MarketBeat News has compared Cullinan Therapeutics (CGEM) and CARGO Therapeutics (CRGX), two small-cap medical companies, concluding that Cullinan Therapeutics is the more favorable investment.

The analysis considered various factors, including institutional ownership, risk, dividends, valuation, analyst recommendations, profitability, and earnings. While both companies boast strong institutional backing, with 86.3% and 93.2% of shares owned by institutions respectively, Cullinan Therapeutics holds a slight edge in insider ownership (6.1% vs. 1.4%).

Despite lower revenue, CARGO Therapeutics exhibits higher earnings than Cullinan Therapeutics. However, a strong consensus target price of $32.00, suggesting a potential upside of 85.72%, places Cullinan Therapeutics in the lead. CARGO Therapeutics, on the other hand, has a target price of $30.33, indicating a potential upside of 25.34%. This bullish outlook for Cullinan Therapeutics, as reflected in analyst recommendations, further solidifies its position as the more attractive investment.

Cullinan Therapeutics is focused on developing oncology therapies for cancer patients, with a lead program targeting solid tumors. Their development pipeline includes multiple therapies for various cancers, including acute myeloid leukemia, myelodysplastic syndrome, and non-small cell lung cancer.

CARGO Therapeutics specializes in developing chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Their lead program, CRG-022, targets CD22, an alternate tumor antigen expressed in B-cell malignancies. They also develop a tri-specific CAR T product candidate targeting multiple B-cell antigen targets.

Ultimately, Cullinan Therapeutics outperforms CARGO Therapeutics in five out of eight key factors considered. Its promising pipeline, strong institutional support, and bullish analyst outlook make it a more appealing investment option for investors seeking exposure to the medical sector.

Read More